Long‐term outcome of cats with acquired myasthenia gravis without evidence of a cranial mediastinal mass

Thomas Mignan; Laurent Garosi; Mike Targett; Mark Lowrie

Long‐term outcome of cats with acquired myasthenia gravis without evidence of a cranial mediastinal mass

2020

Thomas Mignan | Laurent Garosi | Mike Targett | Mark Lowrie

Abstract Background Acquired myasthenia gravis (AMG) is increasingly recognized in cats, yet information regarding the natural history of the disease, treatment, and outcome including occurrence of immune and spontaneous remission remains limited. Objective To determine the long‐term outcome of cats with AMG without evidence of a cranial mediastinal mass (CMM). Animals Eight cats diagnosed with AMG without evidence of a CMM. Methods Retrospective case series. The medical records of cats diagnosed with AMG between 2005 and 2018 from 2 veterinary referral hospitals were reviewed for inclusion. Inclusion criteria consisted of a diagnosis of AMG, thoracic imaging, serum biochemistry including measurement of creatine kinase, and a CBC. Exclusion criteria were the presence of an identifiable CMM, or administration of methimazole or carbimazole. Results All cats had an excellent long‐term outcome, achieving immune remission within 6 months of diagnosis, including 4 cats that did not receive any treatment and whose natural course of disease involved spontaneous remission. Clinical presentation was heterogeneous, and skeletal muscle weakness and fatigability induced or exacerbated by the wheelbarrow exercise stress test were the most consistent abnormalities associated with AMG. Conclusion and Clinical Importance Cats diagnosed with AMG without evidence a CMM have a favorable outcome and frequently achieve immune remission. Moreover, the natural history of AMG in cats includes spontaneous remission when there is no evidence of a CMM. Attempting to rule out the presence of a CMM therefore refines prognosis, and treatment is not always necessary in this disease population.

اظهر المزيد [+]